Spruce Biosciences “announced that a submitted abstract was accepted for poster presentation at the Pediatric Endocrine Society (PES) 2024 Annual Meeting taking place May 2-5, 2024, in Chicago, IL. In the poster presentation, Paul Thornton, M.B.B.S., will highlight baseline characteristics from Spruce’s CAHmelia program evaluating tildacerfont in adult congenital adrenal hyperplasia (CAH), as an illustration of outcomes of current pediatric CAH disease management.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRB:
- Spruce Biosciences’ Compliance Hurdle: Navigating Sarbanes-Oxley to Protect Market Value
- Spruce Biosciences downgraded to Neutral from Buy at H.C. Wainwright
- Spruce Biosciences downgraded to Neutral from Buy at Guggenheim
- Spruce Biosciences downgraded to Neutral from Buy at Ladenburg
- Spruce Biosciences downgraded to Market Perform from Outperform at Leerink
